Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

NCT06488222 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT06488222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06488222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Recruiting
Start date
November 5, 2024
Completion date
August 31, 2027
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer